Abstract
Purpose
The purpose of the present study was to investigate the predictive value of the risperidone metabolic ratio for the individual CYP2D6 genotype.
Methods
The determination of risperidone, 9-hydroxyrisperidone, and CYP2D6 genotype was performed in 89 schizophrenic patients. The receiver operator characteristic (ROC) method and the area under the ROC curve (AUC) were used to illustrate the predictive value of risperidone metabolic ratio for the individual CYP2D6 genotype. The area under the ROC curve (AUC) was used as a global measure of this predictive value. To evaluate the proposed cutoff levels of >1 and <0.1 to identify individuals with a poor or ultrarapid CYP2D6 genotype the sensitivity, specificity, positive predictive value and negative predictive were calculated.
Results
The area under the ROC curve (AUC) for poor and ultrarapid metabolisers was 0.85 and 0.86, respectively. The sensitivity, specificity, positive predictive value and negative predictive value of a risperidone/9–OH-risperidone ratio >1 to CYP2D6 poor metaboliser genotype were 75 %, 95 %, 60 % and 97 %, respectively. The corresponding measures for a metabolic ratio < 0.1 to predict ultrarapid metabolisers were 80 %, 77 %, 18 % and 98 %.
Conclusions
A metabolic ratio > 1 or < 0.1 may be a useful therapeutic biomarker to recommend CYP2D6 genetic testing to guide the present or future treatment of patients in need of psychotropic drugs.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
van Beijsterveldt LE et al (1994) Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. Psychopharmacology (Berlin) 114(1):53–62
Olesen OV et al (1998) Serum concentrations and side effects in psychiatric patients during risperidone therapy. Ther Drug Monit 20(4):380–384
Scordo MG et al (1999) Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berlin) 147(3):300–305
Alfaro CL et al (2000) CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations. J Clin Pharmacol 40(1):58–66
Spina E et al (2001) Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine. Ther Drug Monit 23(3):223–227
Spina E et al (2002) Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. J Clin Psychopharmacol 22(4):419–423
Bondolfi G et al (2002) The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. Pharmacopsychiatry 35(2):50–56
Leon J et al (2007) A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry 40(3):93–102
Mannheimer B et al (2008) Impact of multiple inhibitors or substrates of cytochrome P450 2D6 on plasma risperidone levels in patients on polypharmacy. Ther Drug Monit 30(5):565–569
Dahl ML (2002) Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin Pharmacokinet 41(7):453–470
Cartwright AL et al (2013) Pharmacogenetics of risperidone: a systematic review of the clinical effects of CYP2D6 polymorphisms. Ann Pharmacother 47(3):350–360
Llerena A et al (2013) Pharmacogenetics of clinical response to risperidone. Pharmacogenomics 14(2):177–194
Fleeman N et al (2011) Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. Pharmacogenomics J 11(1):1–14
Ingelman-Sundberg M et al (2007) Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116(3):496–526
Sjoqvist F, Eliasson E (2007) The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants. Clin Pharmacol Ther 81(6):899–902
Ghotbi R et al (2010) Carriers of the UGT1A4 142 T > G gene variant are predisposed to reduced olanzapine exposure–an impact similar to male gender or smoking in schizophrenic patients. Eur J Clin Pharmacol 66(5):465–474
Sachse C et al (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60(2):284–295
Flockhart, D., Drug interactions: Cytochrome P450 Drug Interaction Table. Indiana School of Medicine 2007. Available at: http://medicine.iupui.edu/flockhart/table.htm Accessed August 28, 2013.
Jerling M, Bertilsson L, Sjoqvist F (1994) The use of therapeutic drug monitoring data to document kinetic drug interactions: an example with amitriptyline and nortriptyline. Ther Drug Monit 16(1):1–12
Yasui N et al (1995) Inhibition of trazodone metabolism by thioridazine in humans. Ther Drug Monit 17(4):333–335
Grzybowski M, Younger JG (1997) Statistical methodology: III. Receiver operating characteristic (ROC) curves. Acad Emerg Med 4(8):818–826
Faraggi D, Reiser B (2002) Estimation of the area under the ROC curve. Stat Med 21(20):3093–3106
Wilkinson GR (2005) Drug metabolism and variability among patients in drug response. N Engl J Med 352(21):2211–2221
Acknowledgements
The work was supported financially by the Swedish Society for Medical Research, Stockholm County Council and Karolinska Institutet. We wish to thank Dr Jonatan Lindh for valuable input on data presentation and comments on the manuscript.
Declaration of potential conflicts of interest
The authors declare no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mannheimer, B., Holm, J., Koukel, L. et al. Risperidone metabolic ratio as a biomarker of individual CYP2D6 genotype in schizophrenic patients. Eur J Clin Pharmacol 70, 695–699 (2014). https://doi.org/10.1007/s00228-014-1664-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-014-1664-3